TY - JOUR
T1 - Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults
AU - Mader, J. T.
AU - Norden, C.
AU - Nelson, J. D.
AU - Calandra, G. B.
N1 - Funding Information:
Financial support: This work was supported by a contract to the Infectious Diseases Society of America from the U. S. Food and Drug Administration (no. HHS 223-88-130 I). Correspondence: Dr. Jon T. Mader. Marine Biomedical Institute, Galveston, Texas 77550.
PY - 1992/11
Y1 - 1992/11
N2 - Cases of osteomyelitis can be divided into four categories: acute hematogenous, vertebral, secondary to a contiguous focus of infection without vascular disease, and secondary to a contiguous focus of infection with vascular disease. Each category may be further divided into acute and chronic forms. Clinical symptoms persisting for >10 days correlate roughly with the development of necrotic bone and chronic osteomyelitis. Patients enrolled in clinical trials should generally be >12 years of age. Prior antimicrobial treatment does not exclude patients if the culture of a bone sample obtained at the time of enrollment yields pathogenic bacteria. Randomized, double-blind, active-control comparative studies are encouraged. Clinical outcome should be assessed during therapy and within 5-9 days, 4-6 weeks, and 11-13 months after completion of therapy. In the final assessment, clinical appraisal is paramount.
AB - Cases of osteomyelitis can be divided into four categories: acute hematogenous, vertebral, secondary to a contiguous focus of infection without vascular disease, and secondary to a contiguous focus of infection with vascular disease. Each category may be further divided into acute and chronic forms. Clinical symptoms persisting for >10 days correlate roughly with the development of necrotic bone and chronic osteomyelitis. Patients enrolled in clinical trials should generally be >12 years of age. Prior antimicrobial treatment does not exclude patients if the culture of a bone sample obtained at the time of enrollment yields pathogenic bacteria. Randomized, double-blind, active-control comparative studies are encouraged. Clinical outcome should be assessed during therapy and within 5-9 days, 4-6 weeks, and 11-13 months after completion of therapy. In the final assessment, clinical appraisal is paramount.
UR - http://www.scopus.com/inward/record.url?scp=0026488693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026488693&partnerID=8YFLogxK
U2 - 10.1093/clind/15.Supplement_1.S155
DO - 10.1093/clind/15.Supplement_1.S155
M3 - Article
C2 - 1477223
AN - SCOPUS:0026488693
SN - 1058-4838
VL - 15
SP - S155-S161
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
ER -